| scholarly article | Q13442814 |
| P356 | DOI | 10.1517/17460441.2014.911282 |
| P698 | PubMed publication ID | 24758225 |
| P2093 | author name string | Cristiano Ferrario | |
| Gerald Batist | |||
| P2860 | cites work | Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. | Q46765380 |
| Aromatase inhibitors: from bench to bedside and back | Q46788411 | ||
| Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors | Q48744788 | ||
| Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers | Q50539670 | ||
| Use of the neo-adjuvant exemestane in post-menopausal estrogen receptor-positive breast cancer: a randomized phase II trial (PTEX46) to investigate the optimal duration of preoperative endocrine therapy. | Q51067697 | ||
| Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. | Q53158182 | ||
| Tumor genetic testing for patient selection in phase I clinical trials: the case of PI3K inhibitors. | Q53963513 | ||
| Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. | Q54516956 | ||
| Adjuvant Capecitabine, Docetaxel, Cyclophosphamide, and Epirubicin for Early Breast Cancer: Final Analysis of the Randomized FinXX Trial | Q57278896 | ||
| Molecular prescreening to select patient population in early clinical trials | Q58614572 | ||
| Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer | Q59289357 | ||
| PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro | Q21195212 | ||
| Combination anastrozole and fulvestrant in metastatic breast cancer | Q24595386 | ||
| Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro | Q24615499 | ||
| Comprehensive molecular portraits of human breast tumours | Q24630844 | ||
| Genome sequencing identifies a basis for everolimus sensitivity | Q24631915 | ||
| Continuous cultures of fused cells secreting antibody of predefined specificity | Q26776979 | ||
| Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer | Q27013852 | ||
| Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 | ||
| Lapatinib plus capecitabine for HER2-positive advanced breast cancer | Q27851403 | ||
| Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers | Q27851474 | ||
| Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer | Q27851691 | ||
| Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial | Q27851705 | ||
| Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study | Q27851763 | ||
| Trastuzumab emtansine for HER2-positive advanced breast cancer | Q27851917 | ||
| Activating ESR1 mutations in hormone-resistant metastatic breast cancer | Q27852630 | ||
| Gene expression profiling predicts clinical outcome of breast cancer | Q27860732 | ||
| Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing | Q27860948 | ||
| Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial | Q28254919 | ||
| Identification of selective inhibitors of cancer stem cells by high-throughput screening | Q28255115 | ||
| Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA) | Q28291395 | ||
| Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer | Q28372484 | ||
| Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer | Q29614302 | ||
| Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer | Q29616112 | ||
| Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer | Q29620676 | ||
| Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial | Q30080035 | ||
| Time for more optimism in metastatic breast cancer? | Q30354522 | ||
| Detecting somatic point mutations in cancer genome sequencing data: a comparison of mutation callers | Q30674708 | ||
| Synthetic lethal screen identification of chemosensitizer loci in cancer cells | Q33281866 | ||
| Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy | Q33321322 | ||
| Iniparib plus chemotherapy in metastatic triple-negative breast cancer | Q33393514 | ||
| The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial | Q33408750 | ||
| Both t-Darpp and DARPP-32 can cause resistance to trastuzumab in breast cancer cells and are frequently expressed in primary breast cancers. | Q39870542 | ||
| Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study | Q40340899 | ||
| Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. | Q40462527 | ||
| Effects of novel inhibitors of poly(ADP-ribose) polymerase-1 and the DNA-dependent protein kinase on enzyme activities and DNA repair. | Q40529875 | ||
| Randomized phase III clinical trial designs for targeted agents | Q42165255 | ||
| Comparison of basal-like triple-negative breast cancer defined by morphology, immunohistochemistry and transcriptional profiles | Q42520469 | ||
| Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study | Q42672762 | ||
| Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. | Q42882393 | ||
| Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall | Q43180234 | ||
| Sirolimus and temsirolimus for epithelioid angiomyolipoma | Q43202687 | ||
| Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer | Q43270036 | ||
| Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer | Q43279296 | ||
| Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study | Q43503861 | ||
| Hormonal receptor, human epidermal growth factor receptor-2, and Ki67 discordance between primary breast cancer and paired metastases: clinical impact | Q43521216 | ||
| Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial | Q43739514 | ||
| Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial | Q44045676 | ||
| Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial | Q44102213 | ||
| Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment | Q44102217 | ||
| Proliferation of cancer cells despite CDK2 inhibition. | Q44391102 | ||
| Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, mult | Q44699072 | ||
| Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study | Q44846367 | ||
| Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial | Q44875574 | ||
| Metastatic breast cancer: are we treating the same patients as in the past? | Q45732407 | ||
| Reply to M. Gallén et al and R.S. Midgley et al. | Q45961601 | ||
| Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer | Q46043819 | ||
| Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study | Q46256397 | ||
| Humanized antibodies for therapy | Q46360542 | ||
| Model systems: mechanisms involved in the loss of sensitivity to letrozole | Q46557591 | ||
| Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial | Q46585161 | ||
| Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. | Q46720989 | ||
| Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer | Q46757183 | ||
| Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer | Q33561160 | ||
| Molecular mechanisms of resistance to tumour anti-angiogenic strategies | Q33718025 | ||
| Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. | Q33827808 | ||
| Developing safety criteria for introducing new agents into neoadjuvant trials | Q33895825 | ||
| Similarities and distinctions in the mode of action of different classes of antioestrogens | Q33917000 | ||
| Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. | Q33964848 | ||
| Use of neoadjuvant data to design adjuvant endocrine therapy trials for breast cancer | Q34174466 | ||
| Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex | Q34314489 | ||
| Role of tyrosine kinase inhibitors in cancer therapy | Q34432091 | ||
| Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers | Q34679149 | ||
| Prospective analysis of the impact of VEGF-A gene polymorphisms on the pharmacodynamics of bevacizumab-based therapy in metastatic breast cancer patients | Q34996947 | ||
| Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy | Q35020538 | ||
| Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-bas | Q35023441 | ||
| Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications | Q35040017 | ||
| An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients | Q35064705 | ||
| Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group | Q35552069 | ||
| Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers | Q35583968 | ||
| Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor. | Q35625995 | ||
| Adjuvant trastuzumab in HER2-positive breast cancer | Q35710898 | ||
| Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. | Q35737613 | ||
| Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy | Q35842970 | ||
| Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation | Q35889621 | ||
| The role of BRCA1 in the cellular response to chemotherapy | Q35952250 | ||
| Redundant cyclin overexpression and gene amplification in breast cancer cells | Q36090819 | ||
| CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy | Q36130084 | ||
| Aromatase inhibitors: combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistance | Q36183687 | ||
| BRCA1 and HSP90 cooperate in homologous and non-homologous DNA double-strand-break repair and G2/M checkpoint activation | Q36187310 | ||
| Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era. | Q36395909 | ||
| Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. | Q36494245 | ||
| Neoadjuvant use of hormonal therapy in elderly patients with early or locally advanced hormone receptor-positive breast cancer | Q36655761 | ||
| Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer. | Q36746794 | ||
| Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006 | Q36810717 | ||
| Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers | Q36896061 | ||
| Fulvestrant (Faslodex) -- how to make a good drug better | Q36900695 | ||
| Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics | Q36916152 | ||
| Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved | Q36946008 | ||
| Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers | Q36958682 | ||
| Information-theory based surrogate marker evaluation from several randomized clinical trials with continuous true and binary surrogate endpoints | Q37016467 | ||
| Triple negative tumours: a critical review | Q37048793 | ||
| A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer | Q37087832 | ||
| Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial. | Q37095799 | ||
| Metastatic breast cancer: the role of pegylated liposomal doxorubicin after conventional anthracyclines | Q37116101 | ||
| Phase III clinical trials that integrate treatment and biomarker evaluation | Q37122311 | ||
| Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial | Q37132369 | ||
| Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance | Q37240662 | ||
| Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer | Q37240839 | ||
| Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. | Q37325013 | ||
| Trastuzumab combined with pegylated liposomal doxorubicin in patients with metastatic breast cancer. phase II Study of the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation. | Q37406658 | ||
| Drug-diagnostics co-development in oncology | Q37408558 | ||
| Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways | Q37425090 | ||
| Protein kinase A activation confers resistance to trastuzumab in human breast cancer cell lines | Q37455274 | ||
| Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial | Q37532641 | ||
| Molecular predictors of response to trastuzumab and lapatinib in breast cancer. | Q37660907 | ||
| Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials. | Q37671720 | ||
| Inducing synthetic lethality using PARP inhibitors | Q37734483 | ||
| Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway | Q37813285 | ||
| Mechanisms of resistance to vascular endothelial growth factor blockade | Q37956587 | ||
| Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer | Q37977498 | ||
| mTOR inhibitors in breast cancer: a systematic review | Q38042507 | ||
| Targeted therapy in metastatic colorectal cancer -- an example of personalised medicine in action. | Q38078599 | ||
| A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer | Q38088492 | ||
| Biopsies: next-generation biospecimens for tailoring therapy | Q38116896 | ||
| Appraising iniparib, the PARP inhibitor that never was--what must we learn? | Q38152942 | ||
| Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors | Q38406496 | ||
| Resistance to cancer treatment: the role of somatic genetic events and the challenges for targeted therapies | Q38626744 | ||
| D538G mutation in estrogen receptor-α: A novel mechanism for acquired endocrine resistance in breast cancer | Q39064408 | ||
| Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines | Q39820639 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 647-668 | |
| P577 | publication date | 2014-04-23 | |
| P1433 | published in | Expert Opinion on Drug Discovery | Q5421204 |
| P1476 | title | Advances in the approach to novel drug clinical development for breast cancer | |
| P478 | volume | 9 |
| Q38840175 | Adverse event-related costs for systemic metastatic breast cancer treatment among female Medicaid beneficiaries |
| Q28831422 | KSP inhibitor SB743921 inhibits growth and induces apoptosis of breast cancer cells by regulating p53, Bcl-2, and DTL |
| Q48752979 | Prodigiosenes conjugated to tamoxifen and estradiol. |
Search more.